Alto Neuroscience

Next month our CEO, Amit Etkin will discuss Alto’s recent corporate updates at these investor conferences: Cowen Inc. 44th Annual Healthcare Conference: March 4, 9:50 a.m. ET Leerink Partners Global Healthcare Conference: March 12, 8:00 a.m. ET Stifel Institutional Virtual CNS Days: March 18, 1:00 p.m. ET Details here: https://bit.ly/3QxOOdB

Meet Akash Datwani, Ph.D, VP of Business Development and Strategic Alliances here at Alto, where he is inspired by the opportunity to have a transformative impact on the current treatment paradigm in mental health. Through our #PrecisionPsychiatry platform, we aspire to advance our mission and deliver the right medicines to the right patients.

We're Cure(ious) About the Future of Healthcare. They shared their insights. Part 1: https://lnkd.in/e4-BQKX2   Part 2: https://lnkd.in/eFAXna7R Featuring: Ali Madani, Profluent, Amit Etkin, Alto Neuroscience, Dr Chris Mansi, Viz.ai, Colin Hill, Aitia, Daphne Haim-Langford, PhD, Tarsier Pharma, Eric Kelsic, Dyno Therapeutics, Joe DeVivo, Butterfly Network, Inc., Dr. Judy Chou, AltruBio Inc., Maha Radhakrishnan, Sofinnova Investments , Munjal Shah, Hippocratic AI, Noubar Afeyan, Flagship Pioneering, Peyton Howell, Parexel, Sheila Gujrathi, MD, Biotech CEO Sisterhood, Thijs Spoor, Perspective Therapeutics, Viswa Colluru, PhD, Enveda

We’re excited to announce the granting of the U.S. patent covering ALTO-300 as an adjunctive treatment for patients with #MajorDepressiveDisorder characterized by an #EEG biomarker who have had an inadequate response to an antidepressant. This patent represents the first to cover one of our novel product candidates in combination with a machine-learning derived EEG biomarker, and underscores our novel approach to patient selection in #neuropsychiatric treatment. Read more in our press release here: https://bit.ly/4k6zSAF

Are you attending the ISCTM 21st Annual Scientific Meeting? Our Medical Director, Michael Avissar is presenting a poster on the standardization of EEG enrichment marker acquisition in our ALTO-300 Phase2b #ClinicalTrial for #MajorDepressiveDisorder. Visit our poster on February 20 to learn more. #ISCTM

Today we announced a favorable outcome from the planned interim analysis for the Phase 2b trial of ALTO-300 as an adjunctive treatment for #MajorDepressiveDisorder patients. We are excited to continue this study and look forward to reporting topline results in mid-2026. The favorable outcome from the interim analysis informs the final sample size and marks an important milestone for the ALTO-300 program. Read more in our press release: https://bit.ly/3WYhWyn

Last month, our team came together at our new office for #ExpeditionAlto to refocus on our mission and vision for the year ahead. We also heard from Sarah Jackson, MFT, Ph.D., Associate Professor and Clinical Psychologist, about the patient journey and transformative potential of #PrecisionPsychiatry. We’re energized by the opportunity to reshape #neuropsychiatric care for patients in need. #Altogether

Mental health disorders are the leading cause of disability globally, and many patients struggle due to limitations of currently available treatments. We believe better outcomes can be achieved through precision medicines tailored specifically to address the heterogeneity that exists across patients with #neuropsychiatric conditions. Learn more about how we’re aiming to use insights from our #PrecisionPsychiatry Platform™ to improve clinical outcomes and deliver better solutions. To learn more, tune in to this Bloomberg Vanguards of Health Care podcast episode: https://bloom.bg/412MKQM

In the latest episode of Power’s Power to the Patients Podcast by Brandon Li, our CEO, Amit Etkin, discussed Alto’s founding journey, key learnings along the way and the mission to not only eliminate trial and error in neuropsychiatric treatment, but unlock a new perspective for the field. To learn more about the development and potential of #PrecisionPsychiatry, listen to the full episode here:

#Schizophrenia impacts up to 2.1 million people in the U.S. Despite its prevalence, many still lack access to effective treatment options. At Alto, we're leveraging our #PrecisionPsychiatry Platform™ to develop ALTO-101 as a novel transdermal formulation for the treatment of schizophrenia, with topline data expected in the second half of 2025. Learn more about our work: https://bit.ly/4j8efzq